(Q33619924)

28 July 2017

Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells (English)

1 reference

28 July 2017

0 references

angiogenesis inhibitor

1 reference

inferred from title

author name string

Hiromichi Nakabayashi

series ordinal

1

1 reference

28 July 2017

Toshio Yawata

series ordinal

2

1 reference

28 July 2017

Keiji Shimizu

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

29 June 2010

1 reference

28 July 2017

1 reference

28 July 2017

10

1 reference

28 July 2017

339

1 reference

describes a project that uses

28 July 2017

0 references

0 references

0 references

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-339

0 references

cites work

Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Inhibition of glioma angiogenesis and invasion by SI-27, an anti-matrix metalloproteinase agent in a rat brain tumor model

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Invasiveness corresponds to differentiation rather than to proteinase secretion in endometrial cancer cell lines.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Changing views of the role of matrix metalloproteinases in metastasis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Hyperosmolality suppresses but TGF beta 1 increases MMP9 in human peritoneal mesothelial cells

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Activity of type IV collagenases in benign and malignant breast disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Tumor cell interactions with the extracellular matrix during invasion and metastasis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Protease inhibitors: role and potential therapeutic use in human cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Metalloproteinases and their inhibitors in matrix remodeling

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Secretion of gelatinases and tissue inhibitors of metalloproteinases by human lung cancer cell lines and revertant cell lines: not an invariant correlation with metastasis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

The role of angiogenesis in tumor growth

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

14 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-339

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-339

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-339

Matrix metalloproteinase-2 activation modulates glioma cell migration.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909207

Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma

30 October 2018

1 reference

12 December 2020

Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor

1 reference

12 December 2020

Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166

1 reference

12 December 2020

Halting angiogenesis suppresses carcinoma cell invasion

1 reference

12 December 2020

A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors

1 reference

12 December 2020

Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines

1 reference

12 December 2020

Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023

1 reference

12 December 2020

Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer

1 reference

12 December 2020

Expression of membrane-type matrix metalloproteinase in human gastric carcinomas

1 reference

12 December 2020

Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis

1 reference

12 December 2020

The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth

1 reference

12 December 2020

Activation of human umbilical vein endothelial cell progelatinase A by phorbol myristate acetate: a protein kinase C-dependent mechanism involving a membrane-type matrix metalloproteinase

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-10-339

1 reference

Dimensions Publication ID

28 July 2017

0 references

1 reference

28 July 2017

1 reference